𝔖 Bobbio Scriptorium

✦ LIBER ✦

Are clinical trials of therapeutic agents for MS long enough?

✍ Scribed by Peter Rudge

Book ID: 117311165
Publisher: The Lancet
Year: 1999
Tongue: English
Weight: 67 KB
Volume: 353
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(98)00407-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Guidelines for clinical trials of new th

Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials

✍ D. E. Goodkin; S. Reingold; W. Sibley; J. Wolinsky; H. McFarland; D. Cookfair; F 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

Too much hype, not enough hope: Are bala

Too much hype, not enough hope: Are balanced reporting and proper controls too much to expect from therapeutic studies in animal models of neuromuscular diseases that presage clinical trials in humans?

✍ Allan Bretag 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Structure-based drug design for hypoxia-

Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials

✍ Higashijima, Yoshiki; Tanaka, Tetsuhiro; Nangaku, Masaomi 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 359 KB

Telephone Enhancement of Long-term Engag

Telephone Enhancement of Long-term Engagement (TELE) in Continuing Care for Substance Abuse Treatment: A NIDA Clinical Trials Network (CTN) study

✍ Robert L. Hubbard PhD; Jeffrey D. Leimberger PhD; Louise Haynes MSW; Ashwin A. P 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 156 KB

First line chemotherapy for low or high

First line chemotherapy for low or high risk metastatic breast cancer (LR/HR-MBC) — Are 3 (CMF/FEC) or 2 (NDOC) agents better than 1 (N)? — A multicenter clinical trial of the “IMA”

✍ Souchon, R.; Heidemann, E.; Hirschmann, W.; Minckwitz, G.v. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Commentary on Adjuvant radiotherapy for

Commentary on Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial: Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, and Crawford ED, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

✍ Mark A. Ritter 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 103 KB